Literature DB >> 9302253

Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes.

V Campuzano1, L Montermini, Y Lutz, L Cova, C Hindelang, S Jiralerspong, Y Trottier, S J Kish, B Faucheux, P Trouillas, F J Authier, A Dürr, J L Mandel, A Vescovi, M Pandolfo, M Koenig.   

Abstract

Friedreich ataxia is a progressive neurodegenerative disorder caused by loss of function mutations in the frataxin gene. In order to unravel frataxin function we developed monoclonal antibodies raised against different regions of the protein. These antibodies detect a processed 18 kDa protein in various human and mouse tissues and cell lines that is severely reduced in Friedreich ataxia patients. By immunocytofluorescence and immunocytoelectron microscopy we show that frataxin is located in mitochondria, associated with the mitochondrial membranes and crests. Analysis of cellular localization of various truncated forms of frataxin expressed in cultured cells and evidence of removal of an N-terminal epitope during protein maturation demonstrated that the mitochondrial targetting sequence is encoded by the first 20 amino acids. Given the shared clinical features between Friedreich ataxia, vitamin E deficiency and some mitochondriopathies, our data suggest that a reduction in frataxin results in oxidative damage.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9302253     DOI: 10.1093/hmg/6.11.1771

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  238 in total

1.  Friedreich's ataxia is a mitochondrial disorder.

Authors:  J Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

Review 2.  Disorders related to mitochondrial membranes: pathology of the respiratory chain and neurodegeneration.

Authors:  S Di Donato
Journal:  J Inherit Metab Dis       Date:  2000-05       Impact factor: 4.982

3.  Iron-dependent self-assembly of recombinant yeast frataxin: implications for Friedreich ataxia.

Authors:  J Adamec; F Rusnak; W G Owen; S Naylor; L M Benson; A M Gacy; G Isaya
Journal:  Am J Hum Genet       Date:  2000-08-04       Impact factor: 11.025

4.  New clues on the origin of the Friedreich ataxia expanded alleles from the analysis of new polymorphisms closely linked to the mutation.

Authors:  Antonella Monticelli; Manuela Giacchetti; Irene De Biase; Luigi Pianese; Mimmo Turano; Massimo Pandolfo; Sergio Cocozza
Journal:  Hum Genet       Date:  2004-02-07       Impact factor: 4.132

Review 5.  Friedreich ataxia-update on pathogenesis and possible therapies.

Authors:  Max Voncken; Panos Ioannou; Martin B Delatycki
Journal:  Neurogenetics       Date:  2003-12-19       Impact factor: 2.660

6.  Replication stalling at Friedreich's ataxia (GAA)n repeats in vivo.

Authors:  Maria M Krasilnikova; Sergei M Mirkin
Journal:  Mol Cell Biol       Date:  2004-03       Impact factor: 4.272

Review 7.  Epigenetics in nucleotide repeat expansion disorders.

Authors:  Fang He; Peter K Todd
Journal:  Semin Neurol       Date:  2012-01-21       Impact factor: 3.420

8.  Variations of frataxin protein levels in normal individuals.

Authors:  Therese Boehm; Barbara Scheiber-Mojdehkar; Britta Kluge; Hans Goldenberg; Franco Laccone; Brigitte Sturm
Journal:  Neurol Sci       Date:  2010-05-27       Impact factor: 3.307

Review 9.  Pharmacological treatments for Friedreich ataxia.

Authors:  Mary Kearney; Richard W Orrell; Michael Fahey; Ruth Brassington; Massimo Pandolfo
Journal:  Cochrane Database Syst Rev       Date:  2016-08-30

10.  Protective effects of Fe-Aox29, a novel antioxidant derived from a molecular combination of Idebenone and vitamin E, in immortalized fibroblasts and fibroblasts from patients with Friedreich Ataxia.

Authors:  Matthias L Jauslin; Silvia Vertuani; Elisa Durini; Lisa Buzzoni; Nunzia Ciliberti; Sara Verdecchia; Paola Palozza; Thomas Meier; Stefano Manfredini
Journal:  Mol Cell Biochem       Date:  2007-05-03       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.